Author:
Hygum Katrine,Harsløf Torben,Jørgensen Niklas Rye,Rungby Jørgen,Pedersen Steen B.,Langdahl Bente L.
Funder
Novo Nordisk Scandinavia
UTN
Danish Diabetes Academy
Aarhus University
Aarhus University Hospital
Subject
Histology,Physiology,Endocrinology, Diabetes and Metabolism
Reference60 articles.
1. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6);Buse;Lancet (London, England),2009
2. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial;Davies;Jama,2015
3. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial;Garber;Lancet (London, England),2009
4. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut;Holst;FEBS Lett.,1987
5. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU);Marre;Diabetic Medicine : A Journal of the British Diabetic Association,2009
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献